QNCX Quince Therapeutics, Inc.

$34.04

Quince Therapeutics, Inc. (QNCX) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $1.44 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +7.1% since its last earnings release on August 14, 2026.

Quince Therapeutics Beat Consensus Estimates
Friday, August 14, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 13
Friday · Before Open
Earnings Whisper
-
vs ($1.44)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $21.02

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Quince Therapeutics, Inc.

Quince Therapeutics Inc. is a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases. The company's product pipeline includes NOV004. Quince Therapeutics Inc., formerly known as Cortexyme Inc., is based in Calif.

Sector

Healthcare

Industry

Biotechnology